A Phase II, multicenter, randomized, double-blind, parallel gruop, placebo-controlled, adaptive dose-ranging study to eveluate the efficacy and safety of AIN457 (Secuinumab) (IV) inn patients with relapsing mutiple sclerosis.

Administered By

Awarded By

Contributors

Start/End

  • May 1, 2013 - March 31, 2016